



Depen[®] (penicillamine) – First-time generic

- On January 2, 2020, Par launched an [AB-rated](#) generic version of Mylan's [Depen \(penicillamine\)](#) tablets.
- Depen is approved for the treatment of Wilson's disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy.
- Penicillamine is also available generically as a [capsule](#) that carries the same indications as Depen.
- Depen carries a boxed warning for toxicity, special dosage considerations, and therapeutic benefits.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2020 Optum, Inc. All rights reserved.